WESTINGHOUSE-ELECTRIC
Westinghouse Electric Company and eight European consortium partners today announced that they have received 2 million euros ($2,240,400) in funding from the European Union (EU) to establish the security of supply of nuclear fuel for Russian-designed reactors in the EU. Five EU member states (Bulgaria, Czech Republic, Finland, Hungary and Slovakia) are operating a total of 18 such reactors, which are currently 100 percent dependent on supply from Russian fuel manufacturers. These reactors provide up to 52 percent of the electricity supply in the Member States concerned. The EU funding is aimed at diversifying nuclear fuel sources in the short- to medium-term, in full compliance with international nuclear safety standards. Nuclear energy provides 55 percent of the EU’s low-carbon electricity.
“The decision by the EU to fund this project is significant,” said Yves Brachet, Westinghouse president, Europe, Middle East and Africa Region. “It demonstrates that the EU is serious about taking measures to improve its energy security through a diversification of its nuclear fuel sources. Currently, all Russian reactors in the EU have had to rely on Russian nuclear fuel. The project will help to strengthen and secure European supply of this fuel," said Brachet.
The EU funding comes from the Euratom Research and Training Programme, which is part of Horizon 2020, the EU’s research and innovation program. The project, known as ESSANUF (European Supply of Safe Nuclear Fuel), focuses on licensing alternative nuclear fuel supplies for Russian-designed pressurized water reactors (VVERs) operating in the EU.
Westinghouse will act as the coordinator for the project. Westinghouse’s consortium partners are: VUJE , ÚJV Řež , Lappeenranta University of Technology (LUT), National Nuclear Laboratory (NNL), NucleoCon , National Science Center Kharkov Institute of Physics and Technology (NSC KIPT), Institute for Transuranium Elements of the Joint Research Centre of the European Commission (JRC-ITU) and Enusa Industrias Avanzadas (ENUSA).
Each partner brings leading expertise in their chosen fields: Westinghouse (Sweden and United Kingdom), ENUSA (Spain) and NNL (United Kingdom) have considerable experience in developing, licensing and manufacturing Westinghouse VVER-440 fuel in combination with operating experience at the Loviisa Nuclear Power Plant in Finland. VUJE (Slovakia), ÚJV Řež (Czech Republic), LUT (Finland) and NSC KIPT (Ukraine) have extensive knowledge with regard to safety analysis, licensing and experience in working with the local authorities in their respective countries. The JRC-ITU (EU) and NucleoCon (Slovakia) are experts on the development and adaption of the TRANS-URANUS code which is widely used and commonly available for fault analysis during the licensing process of pressurized water reactors.
There are currently 131 nuclear power plants in the EU, over 60 percent of which are based on Westinghouse technology (US or European in design). Five Member States (Bulgaria, Czech Republic, Finland, Hungary and Slovakia) operate Russian reactors (four VVER-1000 and 14 VVER-440 type reactors).
Westinghouse has previously supplied VVER-440 fuel from its fuel fabrication facility in Preston, U.K., together with ENUSA, to Loviisa (Finland) from 2001 to 2007 in annual fuel load quantities following a successful fuel design and Lead Test Assembly (LTA) program. The fuel operated flawlessly, meeting all regulatory requirements at the highest safety levels. Since 2008, all fuel for the Loviisa nuclear power plant has been supplied by Russia.
Westinghouse is a global nuclear fuel provider for pressurized water reactors (PWRs), including Russian VVER reactors, as well as boiling water reactors (BWRs) and advanced gas-cooled reactors (AGRs). Westinghouse provides nuclear fuel to 143 plants globally, 65 of which are in Europe, and has 10 nuclear fuel manufacturing locations around the world, including two sites in Europe: Springfields Fuels in Preston, U.K., and Westinghouse Electric Sweden in Västerås. Westinghouse is the largest supplier of nuclear fuel in Europe and also the only other fuel manufacturer for VVER-type reactors. In December 2014, Westinghouse and Energoatom, Ukraine's nuclear power plant operator, completed a contract extension for its VVER-1000 reactors. The fuel will be delivered from Westinghouse Electric Sweden.
Westinghouse Electric Company, a group company of Toshiba Corporation (TKY:6502), is the world's pioneering nuclear energy company and is a leading supplier of nuclear plant products and technologies to utilities throughout the world. Westinghouse supplied the world's first pressurized water reactor in 1957 in Shippingport, Pa., U.S. Today, Westinghouse technology is the basis for approximately one-half of the world's operating nuclear plants, including more than 50 percent of those in Europe.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150629005408/en/
Contact:
Westinghouse Europe, Middle East & Africa
Hans Korteweg,
Communications Manager
+32 (0)2 645-7162 (office) / +32
(0)479-75-13-60 (mobile)
kortewh@westinghouse.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum